Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
State Street, in Collaboration with ADIO, to Create 300+ New Jobs With Launch of New Al Ain Operations Hub
